Literature DB >> 25619191

Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008.

Michael B Cook1, Philip S Rosenberg, Frances A McCarty, Manxia Wu, Jessica King, Christie Eheman, William F Anderson.   

Abstract

BACKGROUND: Black men have a higher incidence of prostate cancer than white men in the U.S., but little is known whether incidence or racial differences vary geographically. Understanding these differences may assist future studies on causes of prostate cancer. To address such, we leverage the unique resource of the National Program of Cancer Registries (NPCR) combined with Surveillance, Epidemiology and End Results (SEER).
METHODS: Prostate cancer counts and population denominators by race (black, white), age, calendar year, and U.S. census division, for the period 1999-2008, were extracted from NPCR and SEER. We calculated age-standardized incidence rates (ASR) and estimated annual percent changes (EAPC) by race and census division. We assessed black-to-white incidence rate ratios (BWIRR) by census division and by calendar period.
RESULTS: This analysis included 1,713,471 prostate cancer cases and 1,217 million person-years. Black ASRs ranged from 176 per 100,000 person-years in Mountain division to 259 in Middle Atlantic. BWIRRs ranged from 1.20 in Western divisions to 1.72 in Southeastern divisions. EAPCs indicated that prostate cancer incidence is not decreasing in East South Central, unlike all other divisions. White EAPCs displayed similar variations by census division, resulting in modest temporal changes in BWIRRs.
CONCLUSIONS: Within the U.S., there exists significant geographic variability in prostate cancer incidence rates. Although there are large geographic differences in BWIRRs, temporal trends are fairly stable. This may indicate that primary factors affecting prostate cancer incidence rates vary geographically but affect both black and white men to a similar degree. Published 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  SEER program; census division; epidemiology; incidence rate; prostate cancer; regional variation

Mesh:

Substances:

Year:  2015        PMID: 25619191      PMCID: PMC4419784          DOI: 10.1002/pros.22958

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

1.  Limitations of claims and registry data in surgical oncology research.

Authors:  Hari Nathan; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2007-11-07       Impact factor: 5.344

Review 2.  Prostate cancer and race.

Authors:  Otis W Brawley; Ashesh B Jani; Veraj Master
Journal:  Curr Probl Cancer       Date:  2007 May-Jun       Impact factor: 3.187

3.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

4.  Efficient interval estimation for age-adjusted cancer rates.

Authors:  Ram C Tiwari; Limin X Clegg; Zhaohui Zou
Journal:  Stat Methods Med Res       Date:  2006-12       Impact factor: 3.021

5.  Age-specific reference ranges for serum prostate-specific antigen in black men.

Authors:  T O Morgan; S J Jacobsen; W F McCarthy; D J Jacobson; D G McLeod; J W Moul
Journal:  N Engl J Med       Date:  1996-08-01       Impact factor: 91.245

6.  Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.

Authors:  Roxanne Espaldon; Katharine A Kirby; Kathy Z Fung; Richard M Hoffman; Adam A Powell; Stephen J Freedland; Louise C Walter
Journal:  Urology       Date:  2014-01-16       Impact factor: 2.649

7.  Building the infrastructure for nationwide cancer surveillance and control--a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States).

Authors:  Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall
Journal:  Cancer Causes Control       Date:  2003-03       Impact factor: 2.506

8.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute.

Authors:  C Zippin; D Lum; B F Hankey
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

9.  The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.

Authors:  Bret T Howrey; Yong-Fang Kuo; Yu-Li Lin; James S Goodwin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-05-04       Impact factor: 6.053

10.  Case completeness and data accuracy in the Centers for Disease Control and Prevention's National Program of Cancer Registries.

Authors:  Kathleen K Thoburn; Robert R German; Mary Lewis; Phyllis Janie Nichols; Faruque Ahmed; Jeannette Jackson-Thompson
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

View more
  9 in total

1.  Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.

Authors:  Scott P Kelly; Philip S Rosenberg; William F Anderson; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  Eur Urol       Date:  2016-07-27       Impact factor: 20.096

2.  Racial/Ethnic Disparities in Prostate Cancer Incidence, Distant Stage Diagnosis, and Mortality by U.S. Census Region and Age Group, 2012-2015.

Authors:  Siddharth Iyengar; Ingrid J Hall; Susan A Sabatino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-17       Impact factor: 4.254

3.  Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.

Authors:  Yanru Wang; Jennifer A Freedman; Hongliang Liu; Patricia G Moorman; Terry Hyslop; Daniel J George; Norman H Lee; Steven R Patierno; Qingyi Wei
Journal:  Int J Cancer       Date:  2017-06-01       Impact factor: 7.396

Review 4.  Incidence of kidney, bladder, and prostate cancers in Korea: An update.

Authors:  Wan Song; Hwang Gyun Jeon
Journal:  Korean J Urol       Date:  2015-05-27

5.  A Surveillance, Epidemiology and End Results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma.

Authors:  Yuyou Deng; Ran Bi; Zhenhua Zhu; Shengxian Li; Bo Xu; Wakeel Ahmad Rather; Chunxi Wang
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

6.  Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study.

Authors:  Mojtaba Mirzaei; Mahboobehsadat Mirzadeh; Mohsen Mirzaei
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

7.  An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.

Authors:  Michael B Cook; Lauren M Hurwitz; Ashley M Geczik; Eboneé N Butler
Journal:  Eur Urol       Date:  2020-10-20       Impact factor: 20.096

8.  Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide.

Authors:  S Hassanipour-Azgomi; Abdollah Mohammadian-Hafshejani; Mahshid Ghoncheh; Farhad Towhidi; Saeid Jamehshorani; Hamid Salehiniya
Journal:  Prostate Int       Date:  2016-07-25

9.  Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study.

Authors:  Aurora Perez-Cornago; Timothy J Key; Naomi E Allen; Georgina K Fensom; Kathryn E Bradbury; Richard M Martin; Ruth C Travis
Journal:  Br J Cancer       Date:  2017-09-14       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.